You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

Certaines de ces informations ou toutes, dans certains cas, n’apparaissent qu’en Anglais. Vous pouvez demander la version française

Funded Biomarker Testing

Find an overview of funded biomarker testing in Ontario. Information listed includes diagnostic, predictive and prognostic markers, as well as a summary of testing sites.

Disponible en anglais seulement. Vous pouvez demander un version française.

Funded Biomarker Testing

5 items

1p/19q, CDKN2A testing should be performed on patients who test positive for an IDH1 mutation.

Funded Biomarker Disease Site: Central Nervous System (CNS)
Biomarker: 1p/19q, CDKN2A
Testing Method:Single Nucleotide Polymorphism (SNP)
Testing Site: London Health Sciences Centre, Sunnybrook Health Sciences Centre, The Ottawa Hospital, Trillium Health Partners, Unity Health - St. Michael's Hospital, University Health Network

For IDH Wild-Type patients diagnosed with Grade II and III tumours, sequencing should be performed.

Funded Biomarker Disease Site: Central Nervous System (CNS)
Biomarker: +7/-10
Testing Method:Single Nucleotide Polymorphism (SNP)
Testing Site: London Health Sciences Centre, Sunnybrook Health Sciences Centre, The Ottawa Hospital, Trillium Health Partners, Unity Health - St. Michael's Hospital, University Health Network

H3-K27M testing should be performed on patients diagnosed with a glioma tumour in the midline location.

Funded Biomarker Disease Site: Central Nervous System (CNS)
Biomarker: H3-K27M
Testing Method:Immunohistochemistry (IHC)
Testing Site: London Health Sciences Centre, Sunnybrook Health Sciences Centre, The Ottawa Hospital, Trillium Health Partners, Unity Health - St. Michael's Hospital, University Health Network

MGMT testing should be performed on all Grade IV patients > 55, all Grade III patients >55 and IDH wild-type Grade III patients ≤ 55.

Funded Biomarker Disease Site: Central Nervous System (CNS)
Biomarker: MGMT Methylation
Testing Method:Methylation
Testing Site: London Health Sciences Centre, Sunnybrook Health Sciences Centre, The Ottawa Hospital, Trillium Health Partners, Unity Health - St. Michael's Hospital, University Health Network

Reflex testing should be performed on tumours from newly diagnosed adult patients with astrocytic and oligodendroglial tumours, including glioblastomas (all diffuse high-grade gliomas Stage III and IV).

Funded Biomarker Disease Site: Central Nervous System (CNS)
Biomarker: IDH R132H, P53, ATRX
Testing Method:Immunohistochemistry (IHC)
Testing Site: London Health Sciences Centre, Sunnybrook Health Sciences Centre, The Ottawa Hospital, Trillium Health Partners, Unity Health - St. Michael's Hospital, University Health Network